Form 8-K - Current report:
SEC Accession No. 0001213900-24-046692
Filing Date
2024-05-24
Accepted
2024-05-24 16:44:15
Documents
14
Period of Report
2024-05-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0206875-8k_enzo.htm   iXBRL 8-K 23232
2 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN ENZO BIOCHEM, ea020687501ex10-1_enzo.htm EX-10.1 78737
  Complete submission text file 0001213900-24-046692.txt   298400

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE enz-20240523.xsd EX-101.SCH 3000
4 XBRL LABEL FILE enz-20240523_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE enz-20240523_pre.xml EX-101.PRE 22350
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0206875-8k_enzo_htm.xml XML 3555
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Filer) CIK: 0000316253 (see all company filings)

EIN.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-09974 | Film No.: 24985141
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)